Imagenebio Inc (IMA) Stock Price, Quote & News

Company Profile

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, In...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 345 6265

Website: www.inmagenebio.com

Address:

12526 High Bluff Drive, Suite 345, San Diego, United States

J7263 May. 29 at 8:25 PM

$IMA stick in the mud. That opportunity cost 😬

0 · Reply

NVDAMillionaire May. 19 at 7:40 PM

$IMA Outstanding article that hits the mark on IMA's current state. So if you want to refresh your IMA insights or learn about IMA from scratch, this is a must read. https://everyticker.com/quote/IMA/analysis/imagenebio-s-single-asset-gamble-can-a-safer-ox40-inhibitor-justify-the-risk-nasdaq-ima

0 · Reply

BecauseOfScout Apr. 30 at 4:41 PM

$IMA Can’t ignore the 18m vol hammer candle. Small stater started.

0 · Reply

Jcod21 Apr. 16 at 5:44 PM

$IMA low volume day and hanging in there like a champ. Just a pinch of news or gossip and this can find its way 6+. Hang in there longs. The day will come.

0 · Reply

luckysupernova Apr. 15 at 8:13 PM

$IMA so why do they sell ah below the closing price each day. Thats odd to lose money ah or are they shorting ah everyday lol

0 · Reply

permabull869 Apr. 15 at 11:38 AM

$IMA 6+ today?

0 · Reply

Prolmt85 Apr. 14 at 4:04 PM

$IMA come on baby 💰

0 · Reply

Santa34 Apr. 14 at 4:03 PM

$IMA almost green 🟢🔥

0 · Reply

Papakush5005 Apr. 14 at 2:29 PM

$IMA here we go!

0 · Reply

Mad36 Apr. 14 at 1:27 PM

$IMA might be a rebound day

0 · Reply

ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York

2026-05-08T10:12:52.000Z - 27 days ago

ImageneBio price target lowered to $24 from $30 at Leerink

May 7, 2026, 4:05 PM EDT - 4 weeks ago

ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

May 7, 2026, 7:00 AM EDT - 4 weeks ago

ImageneBio Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

ImageneBio Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

ImageneBio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

ImageneBio Proxy statement: Proxy filing

Apr 13, 2026, 7:00 AM EDT - 7 weeks ago

ImageneBio Announces $30 Million Private Placement

Mar 17, 2026, 4:30 PM EDT - 2 months ago

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 10, 2026, 8:00 AM EDT - 3 months ago

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Mar 10, 2026, 7:00 AM EDT - 3 months ago

ImageneBio Annual report: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 3 months ago

ImageneBio Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 3 months ago

ImageneBio to Participate in Leerink Global Healthcare Conference

Feb 10, 2026, 7:00 AM EST - 4 months ago

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

MLTX

Nov 12, 2025, 7:15 AM EST - 7 months ago

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

Nov 12, 2025, 7:00 AM EST - 7 months ago

ImageneBio Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

ImageneBio Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

Sep 8, 2025, 8:00 AM EDT - 9 months ago

ImageneBio Registration statement: Registration Filing

Jul 25, 2025, 11:00 AM EDT - 11 months ago

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

Jul 24, 2025, 7:00 AM EDT - 11 months ago

ImageneBio Quarterly report: Q2 2025

Jul 23, 2025, 9:00 AM EDT - 11 months ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

PSTX

Jul 15, 2025, 4:15 PM EDT - 11 months ago

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

Jul 11, 2025, 8:00 AM EDT - 11 months ago

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

May 8, 2025, 9:30 AM EDT - 1 year ago

ImageneBio Quarterly report: Q1 2025

Mar 5, 2025, 6:00 PM EST - 1 year ago

ImageneBio Annual report: Q4 2024

Dec 23, 2024, 8:37 AM EST - 1 year ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ikena Oncology Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 8:00 AM EST - 1 year ago

ImageneBio Quarterly report: Q3 2024

Aug 8, 2024, 4:15 PM EDT - 1 year ago

Ikena Oncology Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 2:00 AM EDT - 1 year ago

ImageneBio Quarterly report: Q2 2024

Aug 8, 2024, 2:00 AM EDT - 1 year ago

ImageneBio Earnings release: Q2 2024

May 28, 2024, 4:42 PM EDT - 2 years ago

UPDATE – Ikena Oncology Announces Strategic Update

May 28, 2024, 4:15 PM EDT - 2 years ago

Ikena Oncology Announces Strategic Update

May 13, 2024, 4:45 PM EDT - 2 years ago

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

May 13, 2024, 2:00 AM EDT - 2 years ago

ImageneBio Quarterly report: Q1 2024

May 13, 2024, 2:00 AM EDT - 2 years ago

ImageneBio Earnings release: Q1 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

ImageneBio Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

ImageneBio Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 3:00 AM EDT - 2 years ago

ImageneBio Earnings release: Q4 2023

Mar 12, 2024, 3:00 AM EDT - 2 years ago

ImageneBio Annual report: Q4 2023

Feb 27, 2024, 8:00 AM EST - 2 years ago

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Feb 21, 2024, 4:15 PM EST - 2 years ago

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Jan 18, 2024, 4:05 PM EST - 2 years ago

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 2:00 AM EST - 2 years ago

ImageneBio Quarterly report: Q3 2023

Nov 9, 2023, 2:00 AM EST - 2 years ago

ImageneBio Earnings release: Q3 2023

Nov 7, 2023, 8:00 AM EST - 2 years ago

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

Sep 25, 2023, 8:00 AM EDT - 2 years ago

ImageneBio Proxy statement: Proxy Filing

Sep 15, 2023, 8:00 AM EDT - 2 years ago

ImageneBio Proxy statement: Proxy Filing

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology to Participate in September 2023 Investor Conferences

Aug 18, 2023, 8:00 AM EDT - 3 years ago

ImageneBio Registration statement: Registration Filing

Aug 10, 2023, 8:00 AM EDT - 3 years ago

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Aug 10, 2023, 2:00 AM EDT - 3 years ago

ImageneBio Quarterly report: Q2 2023

Aug 10, 2023, 2:00 AM EDT - 3 years ago

ImageneBio Earnings release: Q2 2023

Aug 7, 2023, 7:00 AM EDT - 3 years ago

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

May 24, 2023, 8:00 AM EDT - 3 years ago

Ikena Oncology to Participate in Upcoming Investor Conferences

May 15, 2023, 7:50 AM EDT - 3 years ago

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

May 15, 2023, 7:45 AM EDT - 3 years ago

Ikena Oncology Announces $40 Million Underwritten Offering

May 15, 2023, 2:00 AM EDT - 3 years ago

ImageneBio Quarterly report: Q1 2023

May 15, 2023, 2:00 AM EDT - 3 years ago

ImageneBio Earnings release: Q1 2023

Apr 28, 2023, 8:00 AM EDT - 3 years ago

ImageneBio Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

ImageneBio Proxy statement: Proxy Filing

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 17, 2023, 9:00 AM EDT - 3 years ago

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Mar 14, 2023, 7:00 AM EDT - 3 years ago

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 14, 2023, 3:00 AM EDT - 3 years ago

ImageneBio Earnings release: Q4 2022

Mar 14, 2023, 3:00 AM EDT - 3 years ago

ImageneBio Annual report: Q4 2022

Mar 7, 2023, 8:00 AM EST - 3 years ago

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

Mar 6, 2023, 8:00 AM EST - 3 years ago

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

Feb 28, 2023, 8:00 AM EST - 3 years ago

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

Dec 19, 2022, 4:30 PM EST - 3 years ago

Ikena Oncology Appoints Owen Hughes as Board Chair

Nov 28, 2022, 8:00 AM EST - 3 years ago

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Nov 22, 2022, 7:30 AM EST - 3 years ago

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 10, 2022, 9:00 AM EST - 3 years ago

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

Nov 7, 2022, 8:48 AM EST - 3 years ago

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022, 8:05 AM EST - 3 years ago

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022, 2:00 AM EST - 3 years ago

ImageneBio Quarterly report: Q3 2022

Nov 7, 2022, 2:00 AM EST - 3 years ago

ImageneBio Earnings release: Q3 2022

Oct 26, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

Oct 18, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Oct 5, 2022, 8:05 AM EDT - 3 years ago

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Sep 6, 2022, 7:30 AM EDT - 4 years ago

Ikena Oncology to Participate in September 2022 Investor Conferences

Aug 11, 2022, 7:30 AM EDT - 4 years ago

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

J7263 May. 29 at 8:25 PM

$IMA stick in the mud. That opportunity cost 😬

0 · Reply

NVDAMillionaire May. 19 at 7:40 PM

0 · Reply

BecauseOfScout Apr. 30 at 4:41 PM

$IMA Can’t ignore the 18m vol hammer candle. Small stater started.

0 · Reply

Jcod21 Apr. 16 at 5:44 PM

$IMA low volume day and hanging in there like a champ. Just a pinch of news or gossip and this can find its way 6+. Hang in there longs. The day will come.

0 · Reply

luckysupernova Apr. 15 at 8:13 PM

$IMA so why do they sell ah below the closing price each day. Thats odd to lose money ah or are they shorting ah everyday lol

0 · Reply

permabull869 Apr. 15 at 11:38 AM

$IMA 6+ today?

0 · Reply

Prolmt85 Apr. 14 at 4:04 PM

$IMA come on baby 💰

0 · Reply

Santa34 Apr. 14 at 4:03 PM

$IMA almost green 🟢🔥

0 · Reply

Papakush5005 Apr. 14 at 2:29 PM

$IMA here we go!

0 · Reply

Mad36 Apr. 14 at 1:27 PM

$IMA might be a rebound day

0 · Reply

Jimmytrader35 Apr. 14 at 9:29 AM

$IMA Glad I sold yesterday at 5.60 jheez

0 · Reply

TurdSniper Apr. 14 at 1:18 AM

$IMA Nice drop on this turd ⬇💩

0 · Reply

BearTamerTrading Apr. 14 at 12:23 AM

Top stocks alerted & traded today 👇🏾 $RMSG $SANA $SKYQ $RKTO $IMA Plenty more was captured as well. Congratulations to all members and our fellow retail traders who tapped in today. Here is the replay for proof 👇🏾 My own results are in the comments for the stocks I remembered to snapshot 😅 https://www.youtube.com/live/yN2-sppreac?si=27QuZUyR_qSEtUns

2 · Reply

only1mc Apr. 14 at 12:02 AM

$RMSG was a great day. made out on $IMA and $SKYQ sky rizzi. nothing like RmSG. Still holding onto $AIXI Accumulating many shares fur the run to come. ready for tomorrow

0 · Reply

Candyman_Trader Apr. 13 at 10:53 PM

Trading “in the zone” paid off today. The only rule I broke is not going live for the $RMSG trade at EOD… sold all at 2.73 and ran from my station afterwards 😮‍💨. coulda, shoulda, woulda… 🤷‍♀️ was up 5.9% this morning and finishing account UP 23.4% TODAY! ✅ on $RMSG $RECT $IMA 🛑 on $ARAI $ALMU and$CMCT

0 · Reply

Santa34 Apr. 13 at 10:38 PM

$IMA add more 👍

0 · Reply

Trader1141 Apr. 13 at 10:19 PM

$IMA had news and ended up with 14% gain $RMSG (garbage) no news and ednded up 600%+ Lol….. this stock market is a Casino… forget news, technicals, setups…. Just guess and you might catch a runner 🤣🤣

1 · Reply

defineme44 Apr. 13 at 8:57 PM

$IMA i added thank you

0 · Reply

heydude84 Apr. 13 at 8:30 PM

$IMA So what's with the huge drop AH? Is there any volume to it or just smoke and mirrors?

0 · Reply

topstockalerts Apr. 13 at 8:24 PM

$IMA something feels different about this push… a lot more conviction behind it

0 · Reply

Jimmytrader35 Apr. 13 at 8:20 PM

$IMA retard

1 · Reply

Market Cap	58.06M
Revenue (ttm)	800,000.00
Net Income (ttm)	-45.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,668.75%
Debt to Equity Ratio	0.00

Volume	5,500
Avg Vol	432,322
Day's Range	N/A - N/A
Shares Out	10.65M
Stochastic %K	55%
Beta	0.72
Analysts	Sell
Price Target	$13.00